Arsenic compounds in the treatment of multiple myeloma: A new role for a historical remedy

Clinical Lymphoma and Myeloma

Volumn 7, Issue 3, 2006, Pages 192-198

  Berenson, James R ^a,b   Yeh, Howard S ^a,b  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b Oncotherapeutics Inc   (United States)

Author keywords

Arsenic trioxide; Hematologic cancer; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; DEXAMETHASONE; DIMETHYLARSINOGLUTATHIONE; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; THALIDOMIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BRAIN DISEASE; CANCER RELAPSE; CARDIOMYOPATHY; CELL CULTURE; CHILL; CHINA; CLINICAL TRIAL; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEART ARREST; HEMATOLOGIC MALIGNANCY; HEPATITIS; HUMAN; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; PNEUMONIA; PRESYNCOPE; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SOLID TUMOR; T WAVE INVERSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES;

EID: 34547591628     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.058     Document Type: Review

References (45)

1. Klaassen CD. Heavy metals and heavy-metal antagonists. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2004:1851-1875.
2. Cutler EG, Bradford EH. Action of iron, cod-liver oil, and arsenic on the globular richness of the blood. Am J Med Sci 1878; 75:74-84.
3. Forkner CE, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931; 97:3-5.
4. Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997; 89:3487-3488.
5. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001; 6(suppl 2):3-10.
6. Sun HD, Ma L, Hu Z, et al. Arsenic trioxide treated 32 cases of acute promyelocytic leukemia. Chin J Integrated Tradit West Med 1992; 12:170-172.
7. Zhang P, Wang SY, Hu XH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Rematol 1995; 17:58-62.
8. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354-3360.
9. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-1348.
10. Trisenox™ (arsenic trioxide) [product insert]. Frazer, PA: Cephalon, Inc; 2005.
11. Parmar S, Rundhaugen LM, Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res 2004; 28:909-919.
12. Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006 [Epub ahead of print].
13. Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006 [Epub ahead of print].
14. Miller WH Jr, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62:3893-3903.
15. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99:4079-4086.
16. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 2000; 275:36062-36066.
17. Costantini P, Chernyak BV, Petronilli V, et al. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J Biol Chem 1996; 271:6746-6751.
18. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998; 177:324-333.
19. Grad JM, Bahlis NJ, Reis I, et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 98:805-813.
20. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88:1052-1061.
21. Akao Y, Mizoguchi H, Kojima S, et al. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. BrJ Haematol 1998; 102:1055-1060.
22. Camacho LH, Hong DS, Gutierrez C, et al. Phase-1 trial of ZIO-101, a novel organic arsenic in patients with advanced cancers. J Clin Oncol 2006; 24(18 suppl):605s (Abstract #13041).
23. Duzkale H, Jilani I, Orsolic N, et al. In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. Cancer Chemother Pharmacol 2003; 51:427-432.
24. Rousselot P, Larghero J, Labaume S, et al. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 2004; 72:166-171.
25. Boise LH, Morales AA, Gutman D, et al. In vitro activity of a novel organic arsenical (S-dimethylarsino-glutathione, ZIO-101) against multiple myeloma. Blood 2005; 106:374b (Abstract #5163).
26. Campbell RA, Chen H, Zhu D, et al. Arsenic trioxide shows synergistic anti-myeloma effects when combined with bortezomib and melphalan in vitro and helps overcome resistance of multiple myeloma cells to these treatments in vivo. Blood 2004; 104:677a (Abstract #2467).
27. Campbell RA, Chen H, Zhu D, et al. Ascorbic acid overcomes drug resistance in myeloma and significantly increases the anti-myeloma effects of both arsenic trioxide and melphalan in vitro and in vivo. Blood 2004; 104:678a (Abstract #2470).
28. Dai J, Weinberg RS, Waxman S, et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93:268-277.
29. Munshi NC, Tricot G, Desikan R, et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002; 16:1835-1837.
30. Hussein MA, Saleh M, Ravandi F, et al. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004; 125:470-476.
31. Rousselot P, Larghero J, Arnulf B, et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 2004; 18:1518-1521.
32. Berenson JR, Yang H, Vescio R, et al. Preliminary findings in a phase 1/ 2 study of Trisenox® (arsenic trioxide) dosed twice weekly in patients with advanced multiple myeloma. Hematol J 2003; 4(suppl 1):S255.
33. Bahlis NJ, Cafferty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/ refractory multiple myeloma. Clin Cancer Res 2002; 8:3658-3668.
34. Wu K, van Droogenbroeck J, Beksac M, et al. Treatment with arsenic trioxide, ascorbic acid and dexamethasone in advanced myeloma patients: preliminary findings of a multicenter, phase II study. Blood 2005; 106:367b (Abstract #5135).
35. Berenson J, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 2006; 135:174-183.
36. Borad MJ, Swift R, Berenson JR. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 2005; 19:154-156.
37. Berenson J, Matous J, Ferretti D, et al. A phase I/II trial evaluating the combination of arsenic trioxide, bortezomib and ascorbic acid for patients with relapsed or refractory multiple myeloma. Blood 2005; 106:2565.
38. Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003; 21:3609-3615.
39. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133:881-885.
40. Unnikrishnan D, Dutcher JP, Gart S, et al. Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematol 2004; 124:610-617.
41. Huang CH, Chen WJ, Wu CC, et al. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. Pacing Clin Electrophysiol 1999; 22:965-967.
42. Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98:266-271.
43. Kornblau SM, Jackson CE, Worthing A, et al. A phase 1 trial of a novel organic arsenic S-dimethylarsino-glutathione (ZIO-101) in hematological malignancies. J Clin Oncol 2006; 24(18 suppl):664s (Abstract #16503).
44. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24:937-944.
45. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063-3067.